Second dose of the BNT162b2 mRNA vaccine: Value of timely administration but questionable necessity among the seropositive

This study monitored titers of neutralizing IgG against the receptor-binding domain of the SARS-CoV-2 S1 subunit 14 days post-injection of each dose of the BNT162b2 mRNA Covid-19 vaccine in 401 Greek healthcare workers aged 20–67. After the first dose, titers varied upon age and history of infection...

Descripción completa

Detalles Bibliográficos
Autores principales: Kontopoulou, Konstantina, Ainatzoglou, Alexandra, Nakas, Christos T., Ifantidou, Athina, Goudi, Georgia, Antoniadou, Eleni, Adamopoulos, Vasilios, Papadopoulos, Nikitas, Papazisis, Georgios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2021
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8325516/
https://www.ncbi.nlm.nih.gov/pubmed/34344551
http://dx.doi.org/10.1016/j.vaccine.2021.07.065
_version_ 1783731573891268608
author Kontopoulou, Konstantina
Ainatzoglou, Alexandra
Nakas, Christos T.
Ifantidou, Athina
Goudi, Georgia
Antoniadou, Eleni
Adamopoulos, Vasilios
Papadopoulos, Nikitas
Papazisis, Georgios
author_facet Kontopoulou, Konstantina
Ainatzoglou, Alexandra
Nakas, Christos T.
Ifantidou, Athina
Goudi, Georgia
Antoniadou, Eleni
Adamopoulos, Vasilios
Papadopoulos, Nikitas
Papazisis, Georgios
author_sort Kontopoulou, Konstantina
collection PubMed
description This study monitored titers of neutralizing IgG against the receptor-binding domain of the SARS-CoV-2 S1 subunit 14 days post-injection of each dose of the BNT162b2 mRNA Covid-19 vaccine in 401 Greek healthcare workers aged 20–67. After the first dose, titers varied upon age and history of infection, being lower in the 50+ age group and significantly higher among the seropositive. After the second dose, immunogenicity was significantly boosted in the age 50+ and SARS-CoV-2-naïve individuals, indicating the effectuality of its timely administration, yet questioning its value among the seropositive.
format Online
Article
Text
id pubmed-8325516
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-83255162021-08-02 Second dose of the BNT162b2 mRNA vaccine: Value of timely administration but questionable necessity among the seropositive Kontopoulou, Konstantina Ainatzoglou, Alexandra Nakas, Christos T. Ifantidou, Athina Goudi, Georgia Antoniadou, Eleni Adamopoulos, Vasilios Papadopoulos, Nikitas Papazisis, Georgios Vaccine Short Communication This study monitored titers of neutralizing IgG against the receptor-binding domain of the SARS-CoV-2 S1 subunit 14 days post-injection of each dose of the BNT162b2 mRNA Covid-19 vaccine in 401 Greek healthcare workers aged 20–67. After the first dose, titers varied upon age and history of infection, being lower in the 50+ age group and significantly higher among the seropositive. After the second dose, immunogenicity was significantly boosted in the age 50+ and SARS-CoV-2-naïve individuals, indicating the effectuality of its timely administration, yet questioning its value among the seropositive. Elsevier Ltd. 2021-08-23 2021-07-31 /pmc/articles/PMC8325516/ /pubmed/34344551 http://dx.doi.org/10.1016/j.vaccine.2021.07.065 Text en © 2021 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Short Communication
Kontopoulou, Konstantina
Ainatzoglou, Alexandra
Nakas, Christos T.
Ifantidou, Athina
Goudi, Georgia
Antoniadou, Eleni
Adamopoulos, Vasilios
Papadopoulos, Nikitas
Papazisis, Georgios
Second dose of the BNT162b2 mRNA vaccine: Value of timely administration but questionable necessity among the seropositive
title Second dose of the BNT162b2 mRNA vaccine: Value of timely administration but questionable necessity among the seropositive
title_full Second dose of the BNT162b2 mRNA vaccine: Value of timely administration but questionable necessity among the seropositive
title_fullStr Second dose of the BNT162b2 mRNA vaccine: Value of timely administration but questionable necessity among the seropositive
title_full_unstemmed Second dose of the BNT162b2 mRNA vaccine: Value of timely administration but questionable necessity among the seropositive
title_short Second dose of the BNT162b2 mRNA vaccine: Value of timely administration but questionable necessity among the seropositive
title_sort second dose of the bnt162b2 mrna vaccine: value of timely administration but questionable necessity among the seropositive
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8325516/
https://www.ncbi.nlm.nih.gov/pubmed/34344551
http://dx.doi.org/10.1016/j.vaccine.2021.07.065
work_keys_str_mv AT kontopouloukonstantina seconddoseofthebnt162b2mrnavaccinevalueoftimelyadministrationbutquestionablenecessityamongtheseropositive
AT ainatzogloualexandra seconddoseofthebnt162b2mrnavaccinevalueoftimelyadministrationbutquestionablenecessityamongtheseropositive
AT nakaschristost seconddoseofthebnt162b2mrnavaccinevalueoftimelyadministrationbutquestionablenecessityamongtheseropositive
AT ifantidouathina seconddoseofthebnt162b2mrnavaccinevalueoftimelyadministrationbutquestionablenecessityamongtheseropositive
AT goudigeorgia seconddoseofthebnt162b2mrnavaccinevalueoftimelyadministrationbutquestionablenecessityamongtheseropositive
AT antoniadoueleni seconddoseofthebnt162b2mrnavaccinevalueoftimelyadministrationbutquestionablenecessityamongtheseropositive
AT adamopoulosvasilios seconddoseofthebnt162b2mrnavaccinevalueoftimelyadministrationbutquestionablenecessityamongtheseropositive
AT papadopoulosnikitas seconddoseofthebnt162b2mrnavaccinevalueoftimelyadministrationbutquestionablenecessityamongtheseropositive
AT papazisisgeorgios seconddoseofthebnt162b2mrnavaccinevalueoftimelyadministrationbutquestionablenecessityamongtheseropositive

Ejemplares similares